Clearmind Medicine (CMND) Stock Analysis

What Clearmind Medicine does

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Key metrics

ETFs linked to CMND

Broad-market and Healthcare sector ETFs an investor holding Clearmind Medicine is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMND fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Clearmind Medicine?

Clearmind Medicine trades under the ticker CMND on NASDAQ.

Which exchange is CMND listed on?

CMND is listed on NASDAQ.

What sector does Clearmind Medicine operate in?

Clearmind Medicine is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMND in a portfolio?

PortView shows CMND's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.